Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Nature

• Publication date

  2001-10-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/35097008PMID 11586351
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ADAMTS: a novel family of extracellular matrix proteases.

  2001cited by this paper
• Procollagen II Amino Propeptide Processing by ADAMTS-3

  2001cited by this paper
• Initial sequencing and analysis of the human genome

  2001cited by this paper
• Ficolins and the lectin complement pathway

  2001cited by this paper
• Partial amino acid sequence of purified von Willebrand factor-cleaving protease.

  2001cited by this paper
• Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.

  2001cited by this paper
• Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.

  2001cited by this paper
• Thrombotic thrombocytopenic purpura associated with clopidogrel.

  2000cited by this paper
• Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura

  2000cited by this paper
• ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function.

  2000cited by this paper
• Thrombotic Thrombocytopenic Purpura: A Paradigm Shift?

  2000cited by this paper
• The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family.

  2000cited by this paper
• How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

  2000cited by this paper
• ADAM-TS5, ADAM-TS6, and ADAM-TS7, Novel Members of a New Family of Zinc Metalloproteases

  1999cited by this paper
• Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene.

  1999cited by this paper
• ADAMTS: A novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats

  1999cited by this paper
• Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins.

  1999cited by this paper
• Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

  1998cited by this paper
• Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.

  1998cited by this paper
• von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

  1998cited by this paper
• Comprehensive human genetic maps: individual and sex-specific variation in recombination.

  1998cited by this paper
• Metalloprotease-Disintegrins: Links to Cell Adhesion and Cleavage of TNFα and Notch

  1997cited by this paper
• Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1.

  1997cited by this paper
• Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch.

  1997cited by this paper
• Molecular Cloning of a Gene Encoding a New Type of Metalloproteinase-disintegrin Family Protein with Thrombospondin Motifs as an Inflammation Associated Gene*

  1997cited by this paper
• Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells.

  1997cited by this paper
• Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.

  1997cited by this paper
• Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.

  1996cited by this paper
• A comprehensive genetic map of the human genome based on 5,264 microsatellites

  1996cited by this paper
• Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

  1996cited by this paper
• The VITESSE algorithm for rapid exact multilocus linkage analysis via genotype set–recoding and fuzzy inheritance

  1995cited by this paper
• Avoiding recomputation in linkage analysis.

  1994cited by this paper
• The CUB domain. A widespread module in developmentally regulated proteins.

  1993cited by this paper
• Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations.

  1992cited by this paper
• Comparison of Plasma Exchange With Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura

  1992cited by this paper
• Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

  1991cited by this paper
• Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.

  1989cited by this paper
• Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE).

  1986cited by this paper
• Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma.

  1985cited by this paper
• Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization.

  1985cited by this paper
• Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells.

  1982cited by this paper
• Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.

  1982cited by this paper
• Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia.

  1978cited by this paper

• Late Onset of Congenital TTP: Case Presentation and Review of the Literature.

  2026cites this paper
• The relationships between disseminated intravascular coagulation and time series change of Von Willebrand factor in patients with out-of-hospital cardiac arrest: a retrospective observational study.

  2026cites this paper
• Pregnancy-Associated Thrombotic Thrombocytopenic Purpura: Diagnostic Pitfalls, Therapeutic Strategies, and Emerging Paradigms.

  2026cites this paper
• Unraveling antibody-induced structural dynamics in the ADAMTS13 CUB1-2 domains via HDX-MS

  2025cites this paper
• Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis

  2025cites this paper
• Relapse and beyond: Navigating the long-term clinical impacts of immune thrombotic thrombocytopenic purpura.

  2025cites this paper
• Congenital thrombotic thrombocytopenic purpura: a rare cause of severe neonatal jaundice and hypoxic respiratory failure – a case report

  2025cites this paper
• The Significance of the Amino Acid at Position 2561 in the C4 Domain of Von Willebrand Factor.

  2025cites this paper
• A Mutant Complement Factor H (W1183R) Enhances Proteolytic Cleavage of von Willebrand Factor by ADAMTS13 Under Shear.

  2025cites this paper
• Protein O-Fucosyltransferases: Biological Functions and Molecular Mechanisms in Mammals

  2025cites this paper
• Preventitive and therapeutic effects of a novel humanized anti-GPIbα Fab fragment in a murine model of thrombotic thrombocytopenic purpura.

  2025cites this paper
• Molecular Basis of Thrombotic Microangiopathy.

  2025cites this paper
• Impact of new medications on the treatment of Immune TTP.

  2025cites this paper
• Presumed successful steroid therapy for suspected thrombotic microangiopathy in a dog.

  2025cites this paper
• Rare onset of congenital thrombotic thrombocytopenic purpura during pregnancy: A novel ADAMTS13 gene variant

  2025cites this paper
• Arginine Methylation by PRMT1 Affects ADAMTS13 Secretion and Enzymatic Activity

  2025cites this paper
• Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13's conformation

  2025cites this paper
• Challenges in diagnosing thrombotic thrombocytopenic purpura

  2025cites this paper
• A Disintegrin and Metalloprotease with Thrombospondin Motif, Member 13, and Von Willebrand Factor in Relation to the Duality of Preeclampsia and HIV Infection

  2025cites this paper
• More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism” and on “The different faces of thrombotic thrombocytopenic purpura”

  2025cites this paper
• A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021

  2025cites this paper
• A case report of thrombotic thrombocytopenic purpura with positive ANA activity

  2025cites this paper
• Real-world evaluation of a novel automated method for measuring ADAMTS13 activity using the Ceveron® s100 analyzer.

  2025cites this paper
• Thrombotic thrombocytopenic purpura and pregnancy

  2025cites this paper
• Thrombotic Microangiopathies.

  2025cites this paper
• 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.

  2025cites this paper
• von Willebrand factor and ADAMTS13

  2025cites this paper
• Characterization of autopsy findings including multivisceral glomeruloid vascular bodies in hereditary thrombotic thrombocytopenic purpura with two new variants in ADAMTS13 gene.

  2025cites this paper
• Splenectomy for immune thrombotic thrombocytopenic purpura (iTTP): a systematic review and meta-analysis.

  2025cites this paper
• Thrombotic Thrombocytopenic Purpura in Pediatric Patients

  2025cites this paper
• The impact of the COVID-19 pandemic on incidence and clinical presentation of thrombotic microangiopathies: data from a laboratory centralizing ADAMTS-13 testing in Quebec

  2025cites this paper
• Shear-induced rotation mechanism of VWF A2 domain plays important role in mediating platelet adhesion.

  2025cites this paper
• ADAMTS-13 Prevents VWF-Mediated Gastric Cancer Metastasis.

  2025cites this paper
• Long term follow-up outcomes in congenital thrombotic thrombocytopenic purpura.

  2025cites this paper
• An Expendable Player in Positive Vascular Remodeling? ADAMTS13 Deficiency Does Not Affect Arteriogenesis or Angiogenesis

  2025cites this paper
• Detection of novel duplication variant in ADAMTS13 gene using chromosomal microarray analysis

  2024cites this paper
• Thrombotic Microangiopathy in Pregnancy: Current Understanding and Management Strategies

  2024cites this paper
• Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura

  2024influential citation
• Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, Therapy and Open Issues

  2024cites this paper
• Hereditary TTP/Upshaw–Schulman syndrome: the ductus arteriosus controls newborn survival

  2024cites this paper
• Distinguishing thrombotic thrombocytopenic purpura from primary immune thrombocytopenia accompanied by anemia using the carbon monoxide breath test

  2024cites this paper
• The effect of ADAMTS13 on graft‐versus‐host disease

  2024cites this paper
• [Management of congenital thrombotic thrombocytopenic purpura in the era of recombinant ADAMTS13 protein: Recommendations from the Reference Center for Thrombotic Microangiopathies (CNR-MAT)].

  2024cites this paper
• A novel automated chemiluminescent enzyme immunoassay (CLEIA) for ADAMTS13 activity enables accompanying measurements of the inhibitory autoantibodies.

  2024cites this paper
• Thrombotic thrombocytopenic purpura in a patient with adult-onset Still’s disease: report of a rare entity

  2024cites this paper
• Initial US tertiary health care system experience using caplacizumab in patients with immune thrombotic thrombocytopenic purpura

  2024cites this paper
• DIAGNOSTIC PITFALLS OF HEMOLYTIC ANEMIA DURING THE NEWBORN PERIOD: FETO-MATERNAL KG-BLOOD TYPE INCOMPATIBILITY AND HEREDITARY TTP/UPSHAW-SCHULMAN SYNDROME

  2024cites this paper
• The Highs and Lows of ADAMTS13 Activity

  2024cites this paper
• Evaluating the potential for iodinated radiocontrast agents to interfere with ADAMTS13 activity testing via fluorescence resonance energy transfer methodology

  2024cites this paper
• Genetics of hemostasis: from bedside to bench and back again

  2024cites this paper
• Single-Nucleotide Polymorphisms in Thrombotic Thrombocytopenic Purpura: A Genetic Predisposition to Immune Thrombotic Thrombocytopenic Purpura

  2024cites this paper
• Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism

  2024cites this paper
• Current status and progress of laboratory testing for ADAMTS13

  2024cites this paper
• Rare Case of Congenital Thrombotic Thrombocytopenic Purpura Presenting as Posttransplant Thrombotic Microangiopathy

  2024cites this paper
• Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.

  2024cites this paper
• Exploration of Toxins from a Marine Annelid: An Analysis of Phyllotoxins and Accompanying Bioactives

  2024cites this paper
• Genetic variants contribute to modulation of renal function in patients with immune thrombotic thrombocytopenic purpura

  2024cites this paper
• Congenital thrombotic thrombocytopenic purpura and recombinant ADAMTS13

  2024cites this paper
• Features and Relapse/Refractory Disease Risk Factors of Patients with Acquired Thrombotic Thrombocytopenic Purpura in the Western Mediterranean Region of Turkey

  2024cites this paper
• Thrombotic Microangiopathy in Solid Organ Transplantation

  2024cites this paper
• Therapeutic Plasma Exchange Management for a Pediatric Patient Presenting With Immune Thrombotic Thrombocytopenic Purpura in a Setting of Common Variable Immunodeficiency

  2024cites this paper
• Targeting the von Willebrand Factor-ADAMTS-13 axis in sickle cell disease.

  2023cites this paper
• Plasma VWF: Ag levels predict long-term clinical outcomes in patients with acute myocardial infarction

  2023cites this paper
• Anaesthetic Management in a Parturient with Thrombotic Thrombocytopenic Purpura (TTP) for Emergency Caesarean Section

  2023cites this paper
• The history of thrombotic thrombocytopenic purpura research: a narrative review

  2023cites this paper
• Introductory comments about the special series of thrombotic microangiopathy

  2023cites this paper
• 100 Years of Thrombotic Thrombocytopenic Purpura: A Story of Death and Life

  2023cites this paper
• Congenital thrombotic thrombocytopenic purpura in children

  2023cites this paper
• Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura

  2023cites this paper
• ADAMTS13 conformation influences autoimmune recognition in immune thrombotic thrombocytopenic purpura.

  2023cites this paper
• ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow

  2023cites this paper
• Hemophagocytic lymphohistiocytosis is associated with deficiency and closed conformation of ADAMTS-13

  2023cites this paper
• A Long-Term Follow-Up Study in Immune-Mediated Thrombotic Thrombocytopenic Purpura: What Are the Outcomes?

  2023cites this paper
• Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience

  2023cites this paper
• Physical Contacts Between Mitochondria and WPBs Participate in WPB Maturation

  2023cites this paper
• A Case of Thrombotic Thrombocytopenic Purpura

  2023cites this paper
• Novel ADAMTS13 mutations in a patient with congenital thrombotic thrombocytopenic purpura

  2023cites this paper
• Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group

  2023cites this paper
• Congenital Thrombotic Thrombocytopenic Purpura: A Rare Cause of Recurrent Thrombocytopenia and Anemia

  2023cites this paper
• PB2634: USE OF N-ACETYLCYSTEINE THERAPY IN PATIENTS WITH RELAPSED REFRACTORY THROMBOTIC THROMBOCYTOPENIC PURPURA

  2023cites this paper
• Recombinant ADAMTS-13 Improves Survival of Mice Subjected to Endotoxemia

  2023cites this paper
• A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies

  2023cites this paper
• Hereditary Thrombotic Thrombocytopenic Purpura

  2023cites this paper
• Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023

  2023cites this paper
• Identification of 8 Rare Deleterious Variants in ADAMTS13 by Next-generation Sequencing in a Chinese Population with Thrombotic Thrombocytopenic Purpura

  2023cites this paper
• Coagulation Factor VIII Regulates von Willebrand Factor Homeostasis In Vivo.

  2023cites this paper
• Von Willebrand Factor Synergizes with Tumor-Derived Extracellular Vesicles to Promote Gastric Cancer Metastasis

  2023cites this paper
• Clinical characteristics, treatments, and outcomes of interferon-beta-induced thrombotic microangiopathy: a literature-based retrospective analysis

  2023cites this paper
• Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection

  2023cites this paper
• Adult‐onset Still's disease with concurrent thrombotic microangiopathy: Observations from pooled analysis for an uncommon finding

  2023cites this paper
• Force-induced biphasic regulation of VWF cleavage by ADAMTS13.

  2023cites this paper
• Psychometric evaluation of a patient-reported outcomes instrument for congenital thrombotic thrombocytopenic purpura

  2023cites this paper
• Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications

  2023cites this paper
• N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study

  2023cites this paper
• Clinical Manifestations, Current and Future Therapy, and Long-Term Outcomes in Congenital Thrombotic Thrombocytopenic Purpura

  2023cites this paper
• Evaluation of two fully automated ADAMTS13 activity assays in comparison to manual FRET assay

  2023cites this paper
• Thrombotic Thrombocytopenic Purpura Without Evidence of Microangiopathic Hemolytic Anemia: A Case Report

  2023cites this paper
• Immune and Hereditary Thrombotic Thrombocytopenic Purpura: Can ADAMTS13 Deficiency Alone Explain the Different Clinical Phenotypes?

  2023cites this paper
• Injury-Induced Endotheliopathy: What You Need to Know.

  2023cites this paper
• Autoantibodies enhance ADAMTS13 clearance in patients with immune thrombotic thrombocytopenic purpura.

  2023cites this paper